EPI-743 in Friedreich's Ataxia Point Mutations

EPI-743 in Friedreich's Ataxia Point Mutations.

The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations.

Official Title: A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations.

Sponsor: University of South Florida
Collaborators: Edison Pharmaceuticals Inc, Friedreich's Ataxia Research Alliance